Mineralys Therapeutics, Inc. (MLYS)
- Sector
- Biotechnology
- Last price
- $15.33
- As of
Kresmion compiles this page from MLYS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Mineralys Therapeutics, Inc. (MLYS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.
See the full MLYS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MLYS on one page. Preview it with sample data, then open it live with a free account.
Preview the MLYS dossierActive events for MLYS
- mediumEarnings below estimates
Q3-2026: Missed consensus by 16.9%, EPS $-0.64 vs $-0.5476 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +115% to MLYS (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1228% to MLYS (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +133% to MLYS (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 94% of MLYS (2026Q2)
FREE, NO ACCOUNT
Every event on MLYS, as it fires
You are seeing 5 of 12 events recorded on MLYS since 2026-05-26.
The five above landed across 2 days. The other 7 were recorded on 3 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
MLYS positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC FundCUSIP 603170101 · 2026Q2 | $33M | 0.02% |
| CITADEL ADVISORS LLC FundCUSIP 603170101 · 2026Q2 | $12.6M | 0.01% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 603170101 · 2026Q2 | $10.2M | 0.01% |
| D. E. Shaw & Co., Inc. FundCUSIP 603170101 · 2026Q2 | $9.5M | 0.01% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 603170101 · 2026Q2 | $4.4M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MLYS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on MLYS
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in MLYS on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MLYS in the last 180 days.
Upstream: SEC EDGAR filings for MLYS
Kresmion, "Mineralys Therapeutics, Inc. (MLYS) institutional holdings and SEC filings", data as of 2026-11-05, https://kresmion.com/research/MLYS. Upstream data: SEC EDGAR filings for MLYS.
Link to this data (HTML):
<a href="https://kresmion.com/research/MLYS">Mineralys Therapeutics, Inc. (MLYS) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow MLYS on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MLYS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.